🇺🇸 FDA
Pipeline program

Regiocit solution pour hémofiltration

APHP220257

Approved small_molecule active

Quick answer

Regiocit solution pour hémofiltration for Adult patients hospitalized in intensive care with an indication of EER with ARC during the stay. is a Approved program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Adult patients hospitalized in intensive care with an indication of EER with ARC during the stay.
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials